🧒🧠 Call for Papers: Cephalalgia Topical Collection – Headache in Children and Adolescents Guest Editors: Andrew Hershey, Aynur Ozge, Massimiliano Valeriani Headache disorders in pediatric populations are common, complex, and often under-recognized. This Topical Collection of

New in Cephalalgia Reports! Have you ever wondered what ‘migraine’ is called in other languages, like Arabic? Interestingly, in Arabic, there are two common synonyms for migraine: al-shaqiqah and ṣudā‘ niṣfī. To learn more, check out this paper! https://t.co/iSdYhbThXQ

New in Cephalalgia! Rimegepant 75 mg administered PRN for up to 52 weeks demonstrated a favorable safety profile and was well-tolerated. https://t.co/u6GNdYp76Q #migraine #headache #brain #pain #neurology #neuroscience

New in Cephalalgia! Greater occipital nerve injection in combination with standard verapamil treatment provides faster reduction in attack frequency than verapamil alone and decreases the adverse events over the first 4 weeks after injection. https://t.co/YKhiO1a0KN #migraine

We’re delighted to share that the paper “International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine”, has been selected as essential reading by our Editor-in-Chief, Simona Sacco!

New in Cephalalgia! The phase 3, randomized, double-blind, placebo-controlled SUNRISE trial evaluated eptinezumab 100 mg, 300 mg, or placebo for prevention of chronic migraine among a predominantly Asian population. Eptinezumab demonstrated statistically significant greater

New in Cephalalgia Reports! Real-world study shows that the external combined occipital and trigeminal neurostimulation (eCOT-NS) neurostimulation device reduces monthly headache days over three months, especially with higher adherence, but larger confirmatory studies are needed.

New in Cephalalgia! Classification research is emerging as an important avenue of headache research. It has a multitude of different designs available and many of them do not need advanced equipment. The international headache classification ICHD has developed significantly from

🧠 Neurological conditions are now the leading cause of ill health and disability worldwide. According to the new WHO Global Status Report on Neurology, over 3 billion people — that’s more than 40% of the global population — are affected by neurological conditions every year.

New in Cephalalgia! Headaches are disabling, overlooked, and untreated in the armed forces. This study of 900+ German soldiers shows an urgent need for structured headache care in military settings. #MigraineCare #Cephalalgia #HeadacheAwareness https://t.co/aSEcT0yYwl #migraine

New in Cephalalgia Reports! The Chordate System S020 delivers kinetic oscillation to the nasal mucosa, which is supposed to modulate the parasympathetic outflow Treatment with the Chordate System S020 had no statistically significant effect on acute migraine headache relief.

New in Cephalalgia! Transcranial magnetic stimulation of the dorsolateral prefrontal cortex could be a non-pharmacological treatment option for chronic migraine patients refractory to monoclonal antibodies against CGRP. https://t.co/0gPEE8AxsK #migraine #headache #brain #pain

📢 The IHC 2025 Abstracts are published! The abstracts from the International Headache Congress 2025 are now published in Cephalalgia. Explore the latest research and advances in headache and migraine from around the world. 🔗 Read the full supplement here:

New in Cephalalgia! The importance of treating migraine attacks early – even in youth: A real-world argument for neuromodulation https://t.co/yLvjnKrutW #migraine #headache #brain #pain #neurology #neuroscience

New in Cephalalgia! The PRECLUDE trial demonstrated that onabotA was well tolerated but did not show significant efficacy compared to placebo for the endpoint reducing migraine days from baseline in patients with episodic migraine (EM). The discrepancy in results between the

New in Cephalalgia Reports! Qualitative interviews with uncontrolled headache patients offers valuable insights for systems-level care. https://t.co/iJwCayRDfI #migraine #headache #brain #pain #neurology #neuroscience

New in Cephalalgia! OnabotulinumtoxinA alters pro- and anti-inflammatory dural macrophage response to cortical spreading depression and decreases their number in female mice. OnabotA may have a non-neuronal mechanism of action in migraine. https://t.co/ZBlBYklR23 #migraine

New in Cephalalgia! An international consensus using the Delphi method led to the development of 4 proposed definitions of refractory migraine: refractory migraine, probable refractory migraine, resistant migraine, and treatment-responsive migraine. https://t.co/u6Tx4CrDLq

New in Cephalalgia! Data from 55,261 patients and 586,981 treatments shows that treating within 1-hour of migraine onset with Remote Electrical Neuromodulation (REN) doubles pain-freedom rates, emphasizing the importance of “treat as early as possible”. https://t.co/HsWGXY1SWb

✅ The answer to the Sunday Quiz is: A! 🎯 According to the ICHD-3, hypnic headache lasts 15 minutes up to 4 hours after waking and occurs on ≥10 days per month for > 3 months — not "Occurring on ≥15 days/month for >3 months." #HeadacheKnowledge #ICHD3 #HypnicHeadache